Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

F0200000

Fluocinolone acetonide

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
6α,9α-Difluoro-11β,16α,17α,21-tetrahydroxy-1,4-pregnadiene-3,20-dione, 6α,9α-Difluoro-16α-hydroxyprednisolone 16,17-acetonide, 6α-Fluorotriamcinolone acetonide, Sinalar, Synandone
Empirical Formula (Hill Notation):
C24H30F2O6
CAS Number:
67-73-2
Molecular Weight:
452.49
MDL number:
MFCD00010525
UNSPSC Code:
41116107
PubChem Substance ID:
329799643
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fluocinolone

manufacturer/tradename

EDQM

mp

267-269 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO

InChI

1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1

InChI key

FEBLZLNTKCEFIT-VSXGLTOVSA-N

Gene Information

human ... NR3C1(2908)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluocinolone acetonide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Benjamin P Nicholson et al.
American journal of ophthalmology, 154(6), 969-973 (2012-09-18)
To characterize the phenomenon of dissociation of the 2 components of the sustained-release fluocinolone acetonide implant (Retisert; Bausch & Lomb) during removal or exchange procedures, or both, and to evaluate outcomes after these events. Retrospective, observational case series. Retrospective review
Peter A Campochiaro et al.
Ophthalmology, 119(10), 2125-2132 (2012-06-26)
To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME). Two randomized, sham injection-controlled, double-masked, multicenter clinical trials. Subjects with persistent
Raymond Iezzi et al.
Biomaterials, 33(3), 979-988 (2011-11-04)
Retinal neuroinflammation, mediated by activated microglia, plays a key role in the pathogenesis of photoreceptor and retinal pigment epithelial cell loss in age-related macular degeneration and retinitis pigmentosa. Targeted drug therapy for attenuation of neuroinflammation in the retina was explored
Oliver Comyn et al.
Current opinion in ophthalmology, 24(3), 248-254 (2013-03-23)
Three long-acting corticosteroid implants are now available for the treatment of retinal disease, offering control of macular edema and inflammation for between 6 months and up to 3 years. This review evaluates their efficacy and side-effect profile in comparison with
Soraya Rofagha et al.
Ocular immunology and inflammation, 21(1), 77-78 (2013-01-18)
To describe a case of spontaneous dissociation of a fluocinolone acetonide implant (Retisert) 5 years following implantation. Case report. A patient with chronic uveitis underwent placement of a fluocinolone acetonide implant in the right eye in 2006. The patient's inflammation
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service